Mixed
B-cell depletion (anti-CD20): slow disability worsening in primary progressive MS
Trial timeline
Trial start year. Dot size reflects participants where reported. Only trials that count towards the status are shown.
primary progressive MS · B-cell depletion (anti-CD20)
Controlled trials disagree.
- Trials
- 9
- Running now
- 4
- Controlled phase 2/3 trials
- 4
- People in controlled trials
- 2547
Deciding trials (phase 3): 2 met, 1 did not.
Other linked trials: 6
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 3 · 2019 · Placebo-controlled · MSFT-NCT04035005
Phase 3 · 2011 · Placebo-controlled · MSFT-NCT01194570
The percentage of patients with 12-week confirmed disability progression was 32.9% with ocrelizumab versus 39.3% with placebo (hazard ratio, 0.76; 95% confidence interval [CI], 0.59 to 0.98; P=0.03).
Read by software from the paper's abstractPhase 2/3 · 2004 · Placebo-controlled · MSFT-NCT00087529
Other linked trials: 6
These linked trials do not set the status.
- CONSONANCE EXOngoing
Phase 3 · 2022 · Not randomised
- GAVOTTEMissed main goal
Phase 3 · 2020 · Compared with ocrelizumab
- CONSONANCEOngoing
Phase 3 · 2018 · Not randomised
- MintakaOngoing
Phase 2 · 2026 · Placebo-controlled
- ITT-PMS ExtResult in a paper, not read yet
Phase 2 · 2012 · Not randomised
Phase 1/2 · 2027 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Trials: 4 → 9
- 2026-10-28Status changed from Being tested to Mixed
- 2026-10-27First listed as Being tested
Related hypotheses
- B-cell depletion (anti-CD20): slow disability worsening in NMOSD
- B-cell depletion (anti-CD20): slow disability worsening in relapsing MS
- B-cell depletion (anti-CD20): slow disability worsening in relapsing and progressive MS
- B-cell depletion (anti-CD20): slow disability worsening in secondary progressive MS
- B-cell depletion (anti-CD20): slow disability worsening in MS (type not specified)
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error